Transgene S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRGNF research report →
Companywww.transgene.fr
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
- CEO
- Alessandro Riva
- IPO
- 2021
- Employees
- 144
- HQ
- Illkirch-Graffenstaden, FR
Price Chart
Valuation
- Market Cap
- $122.57M
- P/E
- -3.55
- P/S
- 878.88
- P/B
- 1.09
- EV/EBITDA
- -2.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- -29978.10%
- Net Margin
- -27389.78%
- ROE
- -63.53%
- ROIC
- -27.43%
Growth & Income
- Revenue
- $136.95K · -97.84%
- Net Income
- $-37,509,945 · -10.42%
- EPS
- $-0.26 · 23.53%
- Op Income
- $-41,054,617
- FCF YoY
- -41.10%
Performance & Tape
- 52W High
- $1.62
- 52W Low
- $0.70
- 50D MA
- $1.00
- 200D MA
- $0.79
- Beta
- 0.73
- Avg Volume
- 47
Get TickerSpark's AI analysis on TRGNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TRGNF Coverage
We haven't published any research on TRGNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TRGNF Report →